Compare BWMX & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMX | FDMT |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 644.3M | 695.3M |
| IPO Year | 2019 | 2019 |
| Metric | BWMX | FDMT |
|---|---|---|
| Price | $16.61 | $10.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $27.83 | ★ $31.71 |
| AVG Volume (30 Days) | 82.1K | ★ 619.6K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.11% | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | $18.17 | N/A |
| Revenue Next Year | $25.68 | $70.28 |
| P/E Ratio | $12.54 | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $12.34 | $5.33 |
| 52 Week High | $19.79 | $14.00 |
| Indicator | BWMX | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Betterware de Mexico SAPI de CV is a company in the consumer product goods industry focused on home organization and beauty and personal care products, commercialized through person-to-person selling. The Group operates through two segments: Home organization under the Betterware brand, including kitchen and food preservation, home solutions, bathroom, laundry & cleaning, tech and mobility, bedroom and wellness. Products are sold through catalogues and distributed through distributors and associates. The Beauty and personal care (B&PC) segment under the JAFRA brand, which generates maximum revenue, includes fragrance, color, skin care and toiletries, distributed through leaders and consultants. The Group operates in Mexico, which generates maximum revenue, the United States and Latam.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).